Owing to the increasing adoption of state-of-the-art technologies for eficient R&D outcomes and the consequent intensifying outsourcing in the life sciences industry, the market for Contract Research Organizations (CRO) is envisaging a tremendous boost. The rapid growth of the biopharmaceutical segment, which is expected to reach $2.6 billion in the next 7-8 years is a key driver of the preclinical CRO business. This is primarily due to the sharper focus of the biopharma industry on chronic diseases with unmet needs. Emerging as a phenomenal player in this segment not only in India but all around the world, Dabur Research Foundation (DRF) has positioned itself prolifically in the market to assist acceleration of drug development projects in several therapeutic areas including Oncology, Inflammation, Dermapathology, Cognitive health, Auto-immune conditions, Gut health, and more recently in the Wellness space.
Offering the Finest Preclinical Services
Dabur Research Foundation is a premier Indian Research Organization established in 1979 with a mission to create an ecosystem in the country to converge the best scientific capabilities to bring innovative health care solutions nationally and globally. This includes a sharp focus on end-to-end novel drug development solutions from identification of potential lead molecules to IND-enabling studies. DRF has been seamlessly engaged to bring preclinical services to global Biotech, Pharma, Phytopharmaceuticals, Cosmeceuticals and Academia. DRF was a drug discovery company till the year 2007/2008 before entering into the preclinical space. This experience of taking molecules forward for regulatory submissions has enabled DRF to bring 30 years of experience in drug development as a preclinical service provider to its partners. DRF provides end-to-end preclinical development services starting from In vitro pharmacology, Mechanistic profiling, Translational disease models, Analytical and Formulation development services right up to Regulatory toxicology. “Our services broadly fall into the functional areas of In Vitro & In Vivo Pharmacology, Analytical/Bioanalytical services, Exploratory & GLP Toxicology. We undertake the full battery of IND-enabling services for diverse molecules including NCEs,biologicals, phytopharmaceuticals, generics, and differentiated generic molecules”, says Dr. Anu Singh, Chief Scientific Officer, Dabur Research Foundation (DRF).
Offering services pertaining to drug discovery & development across various verticals such as in vitro pharmacology, in vivo pharmacology, and toxicology, DRF has created a niche in the R&D sector by functioning in accordance with customer’s vision and project goals. Reflecting her insight on the major expectations of customers from Contract Research Organizations and DRF’s quest to meet their expectations, Dr. Anu Singh quotes, “I would like to redefine the customer as a partner here.
The customer entrusts the CRO with their precious R&D projects thus becoming partners in the process. The client expects honest advice and integrity in the data generated by the CRO. We meet these expectations by encouraging open dialogues with the sponsor where the strategy and technicalities of the project are discussed in detail before the initiation of the studies. The project is discussed at all major milestones, sponsors are invited to watch their study and we improvise when and where necessary. In other words, it works in a true knowledge-based partnership model”.
When asked about any specific case study to emphasize DRF’s client-centric approach, Dr. Anu Singh gladly avers, “There are many satisfying stories to share, but I would like to emphasize one of our European projects where we identified new indications for their oncology molecule. Working as partners, we were able to increase the value of the partners’ assets and progress their molecule for more than the indication they had initially visualized. It was very satisfying for each one of our team members”.
A One-Stop-Shop for Clients’ Pre-clinical Needs
DRF has a state-of-the-art OECD GLP compliant facility which is certified since the year 2017. With well-qualified toxicologists and pathologists who have extensive experience in generating safety packages for global regulatory submissions, DRF serves as a one-stop shop for clients’ pre-clinical needs. The USP of Dabur Research Foundation (DRF) lies in its Quality-By-Design (QbD) tools that are used by Biology experts to plan the Design Of Experiments (DOE) along with risk assessment strategies. Known for its impeccable development approach and strategy, almost every research activity at DRF is supplemented with the right equipment, facilities, and dedicated specialists who help customers arrive at the optimal product formulation which is stable, scalable & quality compliant. With its biology teams, Safety assessment teams and the medical practitioners working closely together from the inception of a new product to deriving meaningful results, the exclusiveness of DRF lies in understanding the exact unmet need for the new molecule.
“All of this is used to design a product that may be more bioavailable, more skin permeable, with a higher safety margin than existing formulations or allows for better compliance/acceptability by the intended patient groups”, avers Dr. Anu Singh.
The usp of dabur research foundation (drf) lies in its quality-by-design (qbd) tools for efficacy & safety assessment that are used by innovative experienced biologists to plan the design of experiments (doe) along with risk assessment strategies at the start of each project
Following its core value of adhering to quality and integrity in projects end-to-end, DRF believes in staying as the knowledge partner in whatever it does. Believing in nurturing and crafting creative scientists as a part of building the scientific ecosystem in India, DRF has undertaken an illustrative journey so far. The premium CRO organization is gradually expanding across the globe, as more than 70 percent of its business comes from the US, EU, and APAC countries. In the future, DRF envisions to emerge as one of the most valued preclinical CROs by contributing to the acceleration of the commercialization of new molecules for unmet medical needs.
We use cookies to ensure you get the best experience on our website. Read more...
